Valneva and Pfizer Advance Lyme Disease Vaccine Toward Regulatory Submission

Pfizer and Valneva's Lyme disease vaccine candidate shows over 70% efficacy. Despite a statistical hurdle, they plan to file for approval, targeting a global market with no current vaccine.

Pfizer and Valneva have released pivotal Phase 3 trial results for their jointly developed Lyme disease vaccine candidate. Despite narrowly missing a key statistical endpoint in an initial analysis, both companies have characterized the data as clinically meaningful. Pfizer, the U.S. pharmaceutical giant, is proceeding with its strategy and is now preparing to file for official regulatory approval.

A Lucrative Market Awaits

The commercial opportunity is significant, as there is currently no approved human vaccine for Lyme disease available anywhere in the world. A successful launch would provide a substantial revenue stream for Valneva. Under the terms of the 2020 collaboration agreement, the French biotech firm is eligible for initial milestone payments totaling $143 million, plus future royalties ranging from 14% to 22%. This financial outlook is of particular interest to shareholders following a challenging period for the stock, which has declined 40.21% over the past 30 days and closed at €2.90 on Monday.

Valneva concluded 2025 with €109.7 million in liquid funds and reported a 21% reduction in its operational cash burn.

Efficacy Data and Statistical Hurdles

The vaccine candidate, PF-07307405, demonstrated an efficacy rate exceeding 70% in preventing Lyme disease in individuals aged five years and older within the VALOR trial. However, the first data analysis revealed a statistical complication: an unexpectedly low number of disease cases resulted in a lower bound of the confidence interval of just 15.8%, which fell short of the pre-specified target.

A subsequent, pre-planned analysis provided the necessary supportive data, yielding a lower bound of 21.7%. Pfizer states this confirms the vaccine's potential, especially as no safety concerns were identified during the study.

Additional Milestones on the Horizon

Beyond the regulatory process for the Lyme vaccine, Valneva has other concrete milestones scheduled for this year. The company's management anticipates initial Phase 2 results for its Shigella vaccine candidate, S4V2, by mid-2026. A decision regarding the next development steps for this program is expected in the second half of the current year.